Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).

ABSTRACT: Bruton's tyrosine kinase (BTK) plays a key role in the B-cell receptor (BCR) signaling pathway and confers anti-apoptotic and proliferative properties to malignant B-cells in chronic lymphocytic leukemia (CLL). Small molecule BTK inhibitors were designed to bind BTK's active site and block downstream signaling. These drugs have now been used in the treatment of thousands of patients with CLL, the most common form of leukemia in the western hemisphere. However, adverse effects of early generations of BTK inhibitors and resistance to treatment have led to the development of newer, more selective and non-covalent BTK inhibitors. As the use of these newer generation BTK inhibitors has increased, novel BTK resistance mutations have come to light. This review aims to discuss previously known and

SUBMITTER: Chirino A 

PROVIDER: S-EPMC10742473 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature